Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (28278)	2/19/1999 9:19:00 AM
From: Alper H.YUKSEL	Read Replies (1) \| Respond to of 32384

LGND made the goats section of Motley Fool :) << Gene transcription company Ligand Pharmaceuticals (Nasdaq:LGND - news) gave back $2 1/16 to $10 5/16 after it said Eli Lilly & Co. (NYSE:LLY - news) decided not to pursue the development of three first-generation anti-diabetes compounds in favor of two others.. >> Looks like we'll see single digits again. Apart from my core holdings, I will continue to buy on the dips and sell at the peaks, which has proven a good way to make money with this stock. I view the current weakness as a good opportunity to load up on some LGND. Cheers

To: Cheryl Galt who wrote (28278)	2/19/1999 12:37:00 PM
From: medsunman	Respond to of 32384

Cheryl: Now that the anticipated Lilly pass on Targretin for diabetes has come out, we wait for the Q3 results of the Targetin/Tamoxifen Phase II study. How do you (or anyone else with an informed opinion)see Targretin's potential being limited by the triglyceride problem in the breast cancer market. You mentioned that due to this problem it may only be indicated for ABC (stage IV metastatic breast cancer?), rather than for use following surgery in stage I. Could you please elaborate, and opine as to the diminished potential for Targretin which you foresee as a result. Thanks.